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SUMMARY
Background: Vasoprotective function of endothelial cells is associated, among others, with biosynthesis and
release of nitric oxide (NO), prostacyclin (PGI2), prostaglandin E2 (PGE2), carbon monoxide (CO) and plas-
minogen activator (t-PA). These endothelial mediators calm down activated platelets and leukocytes, prevent
the occurrence of parietal thrombotic events, promote thrombolysis, maintain tissue perfusion and protect vas-
cular wall against acute damage and against chronic remodeling. Endothelial dysfunction in patients suffering
from atherosclerosis or diabetes type 2 is associated not only with suppression in release of the above mediators
but also with deleterious discharge of prostaglandin endoperoxides (PGH2, PGG2), superoxide anion (O2
—, per-
oxynitrite (ONOO—), and plasminogen activator inhibitor (PAI-1). We looked for mechanisms of protective
endothelial function, with a special respect to the differences between peripheral and pulmonary circulation.
Methods: Cultured endothelial cells of bovine aorta (BAEC) were used to study physiological and pharmaco-
logical mechanisms of increasing free cytoplasmic calcium [Ca2+]i. A porphyrinic sensor quantified the release
of NO from BAEC. In cultured human umbilical vein endothelial cells (HUVEC) we looked for induction by
bradykinin (Bk) of mRNAs for a number of enzymes. In blood perfused rat lungs we studied protective role of
NO against injury inferred by lipopolysaccharide on pulmonary microcirculation that was accomplished by
thromboxane A2 (TXA2), platelet activating factor (PAF), cysteinyl-leukotrienes (cyst-LTs) and the comple-
ment system. In vivo we analyzed the influence of Bk, perindopril and quinapril (Ôtissue typeÕ angiotensin con-
verting enzyme inhibitors, ACE-Is) on endothelial function in entire circulation of anaesthetized rats using a
thrombolytic bioassay and EIA for 6-keto-PGF1a and t-PA antigen.
Results: In BAEC Bk via kinin B2 receptors raised in a concentration-dependent manner (1 pM — 10 nM) free
cytoplasmic calcium ions [Ca2+]i, that triggered the release of NO from BAEC. Calcium ionophore (A23187,
1—100 nM) as well as receptor agonists such as adenosine diphosphate (ADP, 10 nM — 1 µM), adrenaline (Adr,
1—10 µM) or acetylcholine (Ach, 10—100 µM) produced a similar rise in endothelial [Ca2+]i as did Bk at a
nanomolar concentration. ÔTissue typeÕ ACE-Is, e.g. quinapril or perindopril acted through accumulation of
endogenous Bk. However, the potency of ACE-I to change endothelial function is by several orders of magni-
tude lower than that for exogenous Bk. In vivo the major difference between thrombolytic actions by quinapril
or perindopril on one hand, and by exogenous Bk on the other was longevity of thrombolysis by ACE I and a
distinct hypotensive action of exogenous Bk. Still, the long-lasting isolated thrombolytic effect of ACE I was
mediated entirely by endogenous Bk as evidenced by the preventive action of icatibant, a kinin B2 receptor
antagonist. Moreover, in vivo the immediate thrombolysis by ACE-I was mediated by PGI2 rather than by NO
or t-PA, as shown by pharmacological analysis, and by direct blood assays of 6-keto-PGF1a and t-PA antigen.
Bradykinin as a mediator of pleiotropic endothelial action of several cardiovascular drugs (e.g. ACE-I) may
complete its mission not only through B2 receptor and [Ca2+ ]i - mediated release of PGI2 or NO. Here, we
describe a new route of the Bk action. Bk mediated induction of the [Ca2+]i-independent, so called ÔinducibleÕ,
endothelial isoenzymes required for generation of CO, PGI2 and PGE2. After 4 hours of incubation of HUVEC
with Bk (10 nM) it induced mRNAs for haemooxygenase 1 (HO-1), cyclooxygenase 2 (COX-2), prostaglandin
E synthase (PGE-S) whereas mRNA for nitric oxide synthase 2 (NOS-2) was weakly affected. We proved also
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BACKGROUND
As early as at the time of discovery of prostacyclin
(PGI2) [1,2] we realised that its generation in the
conductance arteries might constitute a major pro-
tective mechanism against thrombosis and athero-
sclerosis by preventing deleterious invasion of acti-
vated platelets onto vascular wall. Moreover, we
proposed that a selective inhibition of PGI2 syn-
thase by lipid peroxides would break protective
function of endothelial barrier and invite athero-
sclerosis [2]. We also described a transcellular
mechanism by which cytoprotective PGI2 was
biosynthesised in vascular wall when platelets fed it
with the common substrate (PGH2) for PGI2/TXA2
synthases [3]. A similar design of transcellular
biosynthesis occurs during interaction of activated
leukocytes with endothelial cells, but then pro-
inflammatory cysteinyl-leukotrienes (cyst-LTs) are
formed [4—6]. The significance of microcirculation
in inflammatory response cannot be overestimat-
ed; in this system activation of leukocytes in the
blood stream plays a crucial role. Cyclic 3Õ,5Õ-AMP
disarms leukocytes, however, their adenylate
cyclase is insensitive to activation by PGI2; instead
it is activated by PGE2 [4]. This is why the preva-
lence of generation of prostaglandin E2 (PGE2) over
PGI2 in microcirculation [7] makes perfect sense,
especially since inducible PGE2 synthase (PGE-S)
was identified [8]. Garret Fitzgerald et al. [9] not
long ago challenged the dogma that endothelial
constitutive cyclooxygenase 1 (COX-1) would be
exclusively responsible for making PGI2. According
to them inducible COX-2 is also likely to abide
endothelial cells. Knowledge of the eicosanoid sys-
tem in vascular wall is far from complete. The
cytochrome P 450\NADPH dependent pathway
generates 20-hydroxyeicosatetraenoic acid (20-
HETE) [10] and a number of isomeric epoxy-
eicosatrienoic acids (EETs) with opposite effects on
vascular tone. One of EETs is likely to be a vasore-
laxant Ôendothelium-derived hyperpolarizing fac-
torÕ (EDHF) [11—14]. The family of endothelial
mediators still enlarged after the discovery of
endothelium-derived relaxing factor (EDRF) [15],
that was soon identified as nitric oxide (NO) [16],
with a vasorelaxant action mediated by cyclic 3Õ,
5Õ-GMP [17]. An abbreviation EDRF(NO) is some-
times used to distinguish NO made by endothelial
constitutive NO synthase (NOS 3) from NO gener-
ated by neuronal NOS-1 or by inducible NOS-2. In
the body EDRF(NO) exists as a lipophylic free radi-
cal NO— that is inactivated by superoxide anion
(O2
—) close to endothelial surface [18]. This reaction
may lead to formation of inactive nitrate or to ge-
neration of the highly destructive (ONOO—) [19].
Deficiency of the substrate (L arginine) or a NOS
cofactor (tetrahydrobiopterin) may push NOS-3 to
generate O2
— instead of, or along with NO—
[19—21]. In consequence, the formation of
ONOO— is likely to occur, especially because O2
—
reacts more avidly with NO— than with its own
scavenging enzyme - superoxide dysmutase [19].
Endothelial cells release PGI2 and NO in a coupled
manner [18], however, interactions between the
systems synthesising PGI2 and NO remain unclear.
Both inhibition [22] and activation [23-25] of COX
by NO were reported. Freshly, Volker Ulrich (per-
sonal communication) gave a thorough insight into
that problem. It seems that peroxynitrite is a highly
selective and potent inhibitor of PGI2 synthase with
EC50=50 nM. This inhibitory potency of ONOO—
for PGI2 synthase is at least 200-fold stronger than
analogous inhibitory action of lipid peroxides [2];
moreover, ONOO— is much weaker inhibitor of
other enzymes within the prostanoid network. In
that unlike in peripheral circulation, in pulmonary circulation only NO but not PGI2 would play a protective
role. In the blood-perfused lung, endotoxaemia liberates lipids, such as TXA2, PAF and cyst-LTs. These toxic
lipids along with the activated complement mediate pulmonary damage. Pulmonary endothelial nitric oxide is
the only local protector against lung injury evoked by the phagocytised bacterial lipopolysaccharide.
Summary: Summing up, in peripheral circulation endogenous Bk is the most efficient activator of protective
endothelial function. For instance, thrombolytic action of Ôtissue typeÕ ACE-I depends on the Bk-released
PGI2. Acting as an agonist of endothelial B2 kinin receptors Bk rises [Ca2+]i with a subsequent activation of
constitutive COX 1 and NOS-3. This is followed by an immediate release of PGI2 and NO. Moreover, acting as
ÔmicrocytokineÕ Bk induces mRNAs for HO-1, COX-2 and PGE S, the isoenzymes responsible for a delayed
endothelial biosynthesis of CO, PGI2 and PGE2. Activation of HO-1, apart from the CO generation may also
lead to a deficiency in intracellular haeme required as a coenzyme for both COX and NOS. In peripheral circu-
lation Bk-triggered production of PGI2 seems to play a major role in defending endothelium against thrombo-
sis. On the contrary, in pulmonary circulation NO seems to be the major endothelial defender against bacterial
aggression coming from blood.
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this paper we present our data and our opinion on
pathophysiological and pharmacological signifi-
cance of the coupled endothelial release of PGI2
and NO in peripheral and pulmonary circulation.
METHODS
Assay of cytosolic free calcium [Ca2+]i in cultured
endothelial cells of bovine aorta (BAEC)
Endothelial cells were harvested from bovine tho-
racic aorta (BAEC) as described previously [26].
Cells from 2nd passage were used for experiments.
Their homogenity was identified by their typical
cobblestone morphology under the Axiovert 25
Inverted Microscope (Carl Zeiss Jena GmBH,
Germany).
Cytosolic calcium ion [Ca2+]i assay was accom-
plished by the method of Grynkiewicz et al. [27],
namely BAEC (0.5 x 106 cells ml—1)were loaded
with fura-2 by incubation for 60 min at 25¡C with
this fluorescent dye in its membrane permeant
form, i.e. acetoxymethyl ester (fura-2AM) in pre-
sence of bovine serum albumin. Then the extracel-
lular dye was removed by centrifugation and the
cells were resuspended in HBS containing glucose
(5 mM) concentration. Fluorescence was measured
at 37¡C in a spectrofluorimeter with a dual wave-
length excitation, and magnetic stirring (LS 50B,
Perkin-Elmer Corporation, Beaconsfield, U.K.); at
500 nm with the excitation wavelength of 340 nm
and 380 nm. Calibration was completed using
0.2% Triton X-100 for Rmax and 5 mM EGTA for
Rmin. Eventually, levels of cytosolic calcium [Ca2+]i
were calculated according to the equation of
Grynkiewicz et al. [27].
Endothelial release of nitric oxide as measured by
the Mali˜skiÕs electrode
Nitric oxide (NO) was measured using a porphy-
rinic microsensor. This was prepared by cyclic
voltametric scanning that deposited a film of poly-
meric porphyrin (Ni(II) tetrakis(3-methoxy-4-
hydroxyphenyl)porphyrin) on a thermally sharp-
ened carbon fiber electrode, then coated with
nafion as described previously [28]. The microsen-
sorÕs working electrode was placed close (20–5
mm) to the surface of confluent monolayer of BAEC
along with a platinum wire counterelectrode and a
saturated calomel reference electrode. Voltametric
analyser (PAR model 264A) with the current-sensi-
tive preamplifier (PAR model 181) were used for
amperometric measurements at a potential of 0.68
V. NO measurements are standardised using aque-
ous NO standard prepared as described by Jia and
Furchgott [29]. Nitric oxide was measured over a
single BAEC in HankÕs balance solution at 37¡C.
The response time was 0.1 ms and the detection
limit 10—15 M of NO. Bradykinin was used at a con-
centration from 2x10—15 to 1x10—12 M.
Influence of bradykinin on HO-1, COX-2, COX-1,
PGE-S and NOS 2 mRNA expression in HUVEC
Endothelial cells were harvested from human
umbilical vein (HUVEC) according to Jaffe et al.
[30] and cultured as described previously [26].
HUVEC were used for experiments upon reaching
90% confluency in the third passage, which was
carried out in 6-well plates (1x106 cells, NUNC,
Brand Products, Denmark). HUVEC homogenity
was identified by their typical cobblestone mor-
phology under the Axiovert 25 Inverted Micro-
scope (Carl Zeiss Jena GmBH, Germany). Then
after 24 hours of HUVEC incubation in OPTI-MEM
I without fetal bovine serum, cells were stimulated
with Bk (10 nM) for 4 hours and total RNA was iso-
lated by the guanidinum isothocyanate method as
described by Chomczynski and Sacchi [31] using
TRIZOL¤Reagent (Gibco BRL, UK).
Reverse transcription (RT) of total RNA (1 mg) were
perfomed with oligo (dT)12-18 primer and M MLV
reverse transcriptase (Gibco BRL, UK) for 2 hours
at 42¡C. Then, cDNA (1 ml) was amplified with
HotStar Taq Polimerase (QIAGEN, USA) for both
quantitative and qualitative RT-PCR. Specific
mRNAs for HO-1, COX 2, COX 1 and NOS 2 were
quantified by Gene Specific Relative RT PCR Kit
(Ambion, USA) using multiplex RT-PCR protocol
with endogenous 18S rRNA standard and
Competimer¤ technology. PCR reactions were set
up with GeneAmp 9600 machine (Perkin-Elmer,
USA) of the following profile: 95¡C — 15 min and
35 cycles: 94¡C — 30 s, 59¡C — 30 s, 72¡C — 30 s
followed by 72¡C — 10 min elongation and then
samples were placed on ice. Equal volumes of
each sample (5 mL) were run on 3% agarose con-
taining ethidium bromide and images were cap-
tured electronically with DC40 digital camera
(Kodak, USA) and the bands were quantified using
image analysis software (NIH Image, USA). Results
were expressed as ratio of pixel density units for
specific mRNA to internal standard (18S rRNA). For
position and size of observed specific bands, mark-
er M1 (pUC19/MspI, DNA-Gda˜sk II, Poland) was
run in parallel. For qualitative RT-PCR for PGE S
following specific primers were used: primer 1
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(sense) 5Õ-ATGCCTGCCCACAGCCTG-3Õ (40nM)
and primer 2 (antisense): 5Õ-TCACAGGTG-
GCGGGCCGC-3Õ. Oligonucleotide primers were
constructed by Jakobson et al [8], but trunctated
for cloning restriction sites. Primer sets for NOS 2
and internal standard (18S rRNA) was obtained
commercially (Ambion, USA).
Blood assays of 6-keto-PGF1a and t-PA antigen
Blood samples (500 ml) were collected into Eppen-
dorff tubes with indomethacin to yield its final con-
centration of 10 mM, and then stored at —70¡C not
longer than for a week. 6-Keto- PGF1a was assayed
using the enzyme immunoassay kit (Cayman Che-
mical Co, Ann Arbor, MI) and t-PA antigen was
assayed using the enzyme immunoassay kit (Bio-
pool TintElize t-PA antigen, Umea, Sweden). All
results were expressed in ng ml—1.
Thrombolytic assay for activation of entire
endothelial system in rats in vivo
In vivo model for studying of thrombolysis in cats
[32] was adopted to rats [33,34]. Briefly, male
Wistar rats body weight 300—350 g were anaes-
thetised (thiopental 30 mg kg—1 i.p.) and unfractio-
nated heparin at a dose of 800 units kg—1 i.v. was
administered. Extracorporal circulation was estab-
lished between left carotid artery and left jugular
vein, and a collagen strip from rabbit tendon of
Achilles was superfused with arterial blood at a rate
of 1.5 ml min—1. Its weight was continuously moni-
tored by an auxotonic Harvard transducer. Be-
cause of deposition of thrombi [32—35] the strip
gained in weight by 80—120 mg during the first 20
min of superfusion and stayed at that level during
next 3—5 hours of the experiment. Mean arterial
blood pressure (BP) was monitored from right
carotid artery by a Harvard pressure transducer,
and right femoral vein was prepared for drug
administration. In the above system dispersion of
thrombi used to occur next to intravenous adminis-
tration of PGI2 or iloprost at doses of 0.1—1.0 mg
kg—1 (without concomitant fall in BP) and next to
glyceryl trinitrate at doses of 30—100 mg kg—1 or
metacholine hydrochloride (10 mg kg—1) or
kallikrein (100 units kg—1) (with accompanying fall
in BP) whereas aspirin at doses of 5—50 mg kg—1 did
not evoke thrombolysis. Streptokinase (3—30
megaunits kg—1) produced biphasic thrombogenic /
thrombolytic response [36].
Blood-perfused rat endotoxaemic lungs
Lungs were isolated from Wistar rats weighing
200—250g (Lod: WIST BR from Animal laboratory
of Polish MotherÕs Memorial Research Institute
Hospital in üd, Poland) and mounted in an iso-
lated rat lung set-up (Hugo Sachs Elektronik) as
described previously [37]. Briefly, anaesthetised
rats (thiopentone 120 mg kg—1, i.p.), after laparato-
my, were exsanguinated by incision of left renal
artery and lungs were exposed via medial sternoto-
my. The pulmonary artery and left atrium were
cannulated via right and left atrium, respectively.
Immediately after cannulation lungs were dissected
from the thorax and mounted in the water-jacke-
ted (37¡C), air-tight glass chamber (HSE), and venti-
lated with negative pressures. The end-expiratory
pressure in the chamber was set to be —2 cm H2O
and inspiratory pressure was adjusted between -6
to —10 cm H2O to yield the initial tidal volume
(TV) of about 2.0 ml. Lungs were perfused with
various fluids using a peristaltic pump (ISM 834,
HSE) at constant flow of about 16 ml min—1.
Following parameters were measured: arterial and
venous pulmonary pressures (PAP, PVP) tidal vo-
lume (TV) and the weight of lungs according to the
UhligÕs method [38]. The following fluids were
used to perfuse the lung preparation: rat full blood
(FB), rat platelet rich plasma (PRP), rat platelet poor
plasma (PPP) or Krebs-Henseleit buffer (KH) ob-
tained as described previously [37].
All lungs preparations were allowed to equilibrate
for the first 15 min until baseline PAP, PVP, TV and
weight became stable. LPS was injected 45 min-
utes after the beginning of the experiment. L-
NAME was administered 15 min prior to LPS.
Camonagrel (300 mM), WEB 2170 (100 mM), MK
571 (100 mM), anti-CD62P (1 mg ml—1) sCR1 (100
mg ml—1) were added 30 min prior to injection of
LPS.
Data were expressed as means–SEM of changes in
TV (DTV), PAP (DPAP), PVP (DPVP), or weight
(Dweight) from values 30 min before LPS injection.
Reagents
Bradykinin (Bk), adrenaline hydrochloride, adeno-
sine diphosphate (ADP), acetylocholine hydrobro-
mide, indomethacin, NG nitro-L-arginine methyl
ester (L NAME), calcium inophore A23187, Fura
2AM, lipopolysaccharide from Escherichia coli
(LPS, B: 0127) were purchased from Simga-Aldrich
(USA). Platelet activating factor (PAF) receptor
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antagonist WEB2170 was obtained from Boehrin-
ger-Ingelheim (Germany), thromboxane A2 syn-
thase inhibitor camonagrel from Ferreir (Spain),
cysteinyl-leukotriene receptor antogonist (MK571)
from Biomol (USA), anti-selectin P policlonal anti-
body (anti-CD62P) from Pharmingen (Germany)
and alternative and classic pathway complement
inhibitor (sCR1) from T CELL Boston (USA). Angio-
tensin converting enzyme inhibitors (ACE I); quina-
pril, quinaprilat were gifts from Pfizer Poland and
perindopril, perindoprilat from Servier Poland.
Bradykin B2 receptor antagonist icatibant (HOE
140) was a gift from Hoechst Marion Roussel
(Germany).
Statistical analysis
Arithmetical means are given with s.e. mean (SEM).
Differences between groups were assessed with
unpaired two-tailed t test with WelchÕs correction
or paired StudentÕs t-test. P less than 0.01 was
assumed to denote a significant difference. In iso-
lated lung experiments difference between groups
were assessed by one-way ANOVA followed by
post hoc Fischer test. P less than 0.05 was consi-
dered as statistically significant.
RESULTS
Effect of bradykinin on cytosolic free calcium
[Ca2+]i and NO release in BAEC
Despite standardized conditions (see Methods),
[Ca2+]i in resting or stimulated cells varied between
experiments. Basal [Ca2+]i were 50—150 nM (the
most often reading was 100 nM). After instillation
of the standard Bk concentration (10 nM) the rise
in [Ca2+]i was 4 to 8 fold. Calcium ionophore
(A23187) produced a concentration dependent
(1—100 nM) rise in [Ca+2]i. Similar rise in [Ca+2]i
was obtained by the following agonists of endothe-
lial receptors: bradykinin (1 pM — 10 nM), adeno-
sine diphosphate (10 nM — 1 mM), adrenaline
(1—10 mM), acetylcholine (10—100 mM), as well as
by ACE inhibitors perindopril and quinapril (10—30
mM) (Fig. 1). Effect of Bk (10 nM) on [Ca+2]i was
effectively blocked by icatibant (30 nM), a B2 kinin
receptor antagonist (Fig. 2).
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Figure 1. Increase in intracellular free calcium levels [Ca+2]i in cultured
bovine endothelial cells (BAEC, 2nd passage) by bradykinin
(Bk, 10 nM and 1 pM, solid lines), calcium ionophore
(A23187, 10nM, 1 nM, dotted lines, [a]), adrenaline (10 mM,
1 mM and 0.1 mM, dotted lines, [b]), adenosine diphosphate
(ADP, 1 mM, 0.1 mM and 0.01 mM, dotted lines, [c]) and
angiotensin converting enzyme inhibitors (ACE-I, perindopril
(30 mM), quinapril (30 mM), dotted lines, [d]).
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Sensitivity to Bk varied between batches of BAEC.
In the most sensitive batch of BAEC a rise in [Ca2+]i
occurred after instillation of Bk at a concentration
as low as 1 fM (Fig. 3, left panel). Basal NO release
by BAEC was 12 nM. Bk in a concentration-depen-
dent manner (2 f M- 10 f M) stimulated within one
second NO release from BAEC. Bk at higher con-
centrations of 10 fM to 1 pM kept NO release at
the level of 535–25 nM NO (Fig. 3, right panel).
Effect of bradykinin on mRNAs for HO-1, COX-2,
COX-1, PGE-S and NOS 2 in HUVEC
To compensate for variations in total RNA quality,
initial quantification errors and random tube-to-
tube variation in reverse transcription and PCR, we
used multiplex RT PCR with two primer sets in one
tube in a single PCR (multiplex). One set of primers
was used to amplify the cDNA of interest: HO 1,
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Figure 2. Inhibition by icatibant (30nM, dotted line) of increase in
[Ca+2]i by Bk (10nM, solid line) in BAEC. Dashed line shows
the icatibant (30 nM) had no effect of its own on [Ca+2]i.
Figure 3. The effect of Bk (1 fM, 1 pM and 10 nM) on [Ca+2]i in BAEC
(left panel) and the effect of Bk (10—15 — 10—12 M) on the sur-
face concentration of nitric oxide in BEAC.
Figure 4. Multiplex RT-PCR with an endogenous standard (18S rRNA)
of RNAs for HO-1, COX-2, COX-1 and NOS-2. Lane 1 dis-
plays mass standards (sizes of the DNA marker M1 are
printed at left). Lanes 2, 3 and 4 contain cDNA obtained from
unstimulated HUVEC, lanes 5, 6 and 7 contain cDNA from Bk
(10 nM)-stimulated HUVEC for 4 hrs. cDNAs in lanes 2, 3, 4
and 5, 6, 7 were diluted 1:10, 1:20 and 1:30, respectively.
The data obtained are expressed as x-fold difference in the
level of specific mRNA and the level of internal standard
(18S rRNA) and are shown at right.
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COX 2, COX 1, and NOS 2 while second set of
primers was used to amplify an invariant endoge-
nous control 18S rRNA. Fig. 4 shows representative
gels and relative RT PCR is expressed by x-fold dif-
ference in the level of specific mRNA between
equivalent total RNA samples. In HUVEC incuba-
ted for 4 hours with bradykinin at a concentration
of 10 nM, a significant increase in mRNAs for HO-
1 (4.5-fold) and COX-2 (2.5 fold), but not for COX-
1 (1.35 fold) and NOS 2 (0.3 fold) was observed.
In separate RT-PCR experiments, the induction of
specific PGE-S mRNA, but not NOS 2 mRNA was
observed. Fig. 5 shows a gel with the band of
induced PGE-S with hardly visible band of NOS 2.
Total RNA content was controlled by amplifying
invariant control 18S rRNA.
In vivo activation of the entire endothelial system
in rats by bradykinin and by ACE I as measured
by the thrombolytic assay
In rats with extracorporal circulation both perindo-
pril and quinapril at doses 10—30 mg kg—1 produced
a long lasting (>4 hrs) thrombolysis with no
hypotensive effect. The same doses of perindopri-
lat and quinaprilat (active metabolites of the drugs)
produced a shorter (< 2 hrs) thrombolytic effect,
again with no concomitant fall in blood pressure.
Exogenous Bk (1—30 mg kg—1) produced a short-las-
ting thrombolysis and a profound arterial hypoten-
sion (Fig. 6) All of the above effects were inhibited
by pretreatment with icatibant at a dose of 100 mg
kg—1. Thrombolysis by quinapril and perindopril
was also abolished by pretreatment with indome-
thacin (5 mg kg—1), while L NAME (5 mg kg—1) only
partially and temporally inhibited thrombolytic
response to ACE-I (Fig. 7). Quinapril and perindo-
pril at doses 30 mg kg—1 within first 15 min after
intravenous injection raised blood levels of 6-keto-
PGF1a (Fig. 8). These elevated levels of PGI2 break-
down product would be staying for next 3—4 hrs till
thrombolysis lasted (Fig. 7, 8). t PA antigen plasma
concentration started to rise significantly only 1 hr
after administration of ACE Is and then continued
to rise during the observation period (Fig. 8). As
mentioned above a long-lasting thrombolytic res-
ponse to quinapril (Fig. 7) was associated with a
concomitant rise in blood level of 6-keto-PGF1a.
Cyclooxygenase inhibition by indomethacin (5 mg
kg—1 i.v.) was evidenced by eradicating the bio-
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Figure 5. RT-PCR of mRNAs for PGE-S, NOS-2 (upper gel) and 18S
rRNA (house keeping gene, lower gel) in unstimulated and
Bk (10 nM) stimulated for 4 hours HUVEC. Positions and
sizes of the DNA marker M1 are printed at left.
Figure 6. Effects of exogenous Bk (30 mg kg—1) and endogenous Bk
(perindoprilat, 30 mg kg—1) on arterial blood pressure (BP)
and blood-superfused thrombus weight (THR) in rats #1
and #2.
Figure 7. Pharmacological analysis of thrombolytic action (THR) of
quinapril (30 mg kg—1, i. v, rat #1). Effects of the pretreat-
ment with icatibant (100 mg kg—1, i. v, rat #2), indomethacin
(5 mg kg—1, i. v, rat#3) and L-NAME (5 mg kg—1, i. v, rat#4).
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chemical response to quinapril. In blood no rise in
the decomposition product of PGI2 occurred (data
not shown). This clear cut effect of indomethacin
was coupled with loss of thrombolytic properties of
quinapril (Fig. 7). Interestingly, pretreatment with
L-NAME (5 mg kg—1, i.v.) not only delayed throm-
bolysis by quinapril (Fig. 7). Absence of the endo-
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Figure 8. Time-dependent (0 — 180 min) effects of quinapril ( n 30 mg
kg—1, i. v.) and perindopril (n 30 mg kg—1, i. v.) in rats on plasma
or blood levels of t-PA antigen (n=8) or 6-keto-PGF1a(n=6)
(mean–SEM) (p<0.01 as compared with time 0.
Figure 9. Time-dependent (0—90 min) changes in blood levels of 6-
keto-PGF1a in rats after intravenous administration of
quinapril (30 mg kg—1) administration before (l ) and after
(n ) pretreatment with L-NAME (5 mg kg—1, i. v.),
(mean–SEM, n=4).
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Figure 10. Blood-perfused rat lungs. Early response to lipopolysaccha-
ride (LPS, 300 mg ml—1) before (s ) and after (m ) pretreat-
ment with (L-NAME, 300 mM). LPS produced immediate
but transient constriction of pulmonary vessels (DPAP and
DPVP) and a fall in tidal volume (DTV). Within next 2 hrs
only a decrease in DTV was agravated. After pretreatment
with L-NAME LPS produced an abrupt and irreversible rise
in DPAP, DPVP and a fall in DTV accompanied by pul-
monary oedema. Data show mean–SEM for n=6 experi-
ments.
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genous source of NO did also hindered quinapril-
induced appearance of 6-keto-PGF1a in blood
(Fig. 9).
Role of endogenous NO in the immediate
response of isolated blood-perfused rat lung to
lipopolysaccharide (LPS)
Injection of LPS (300 mg ml—1) into the isolated
blood-perfused rat lungs induced a biphasic
response. An immediate transient phase of this
response consisted of an increase in pulmonary
arterial and venous pressures (PAP and PVP) with a
simultaneous decrease in tidal volume (TV). This
response was not accompanied by a significant
change in weight of the lung. A delayed phase of
lung response to LPS consisted of a gradual decline
in TV without accompanying changes in TV, PAP
PVP and weight (Fig 10). After pretreatment with L
NAME (300 mM), injection of LPS (300 mg ml—1) led
to the immediate arrest of lung function. L-NAME
+ LPS - induced immediate rise in PAP and PVP as
well as drop in TV were substantially augmented as
compared to the response evoked by LPS alone,
and were accompanied by a profound lung oede-
ma (Fig. 10).
These responses were not seen in lungs perfused
with plasma or Krebs-Henseleit buffer. Interestin-
gly, during an immediate lung response to LPS and
L-NAME + LPS there was a comparable pool of
leukocytes (data not shown) and platelets seques-
tered within pulmonary circulation, the latter in
response to LPS (Fig. 11).
Immediate lung responses to LPS or L-NAME+LPS
were both abrogated by a complement inhibitor
sCR1 (100 mg ml—1). Responses induced by LPS and
L-NAME+LPS were also affected by inhibitors of
lipid mediators. Immediate transient lung response
to LPS was inhibited by PAF receptor antagonist,
WEB 2170 (100 mM), and a TXA2 synthase inhibi-
tor, Camonagrel (300 mM), but not by a leukotrie-
ne receptor antagonist MK 571 (300 mM), whereas
immediate irreversible lung response to L-
NAME+LPS was inhibited by WEB 2170 (100 mM),
Camonagrel (300 mM) as well as by MK 571 (300
mM). Responses induced by L-NAME+LPS but not
that induced by LPS were inhibited by antibody
against selectin P, anti-CD62P (1 mg ml—1) (data not
shown).
At the morphological level, the immediate transient
lung response induced by LPS did not leave any
signs of injury in the lung histology. However, irre-
versible response induced by L-NAME+LPS was
associated with alveolar haemorrhagic oedema and
a damage of alveolar barrier as evidenced by light
and electron microscopy (Fig. 12, 13). Importantly,
electron microscopy also revealed that sequestra-
tion of neutrophils and platelets during an immedi-
ate phase of lung response to LPS was confined to
pulmonary microcirculation and associated with
internalisation of LPS by neutrophils (Fig. 14).
DISCUSSION
Cultured endothelial cells from bovine aorta
(BAEC) or from human umbilical vein (HUVEC)
have a capacity to generate two major endothelial
mediators, i.e. prostacyclin (PGI2) and nitric oxide
(NO). Constitutive enzymes responsible for that
generation are dioxygenases, namely, cyclooxyge-
nase 1 (COX-1) and nitric oxide synthase (NOS-3).
Inside the cells these enzymes are activated by a
rise in free cytoplasmic calcium ions [Ca2+]i. Here
we report that in BAEC calcium ionophore (A
23187, 1—100 nM), and a number of physiological
receptor agonists such as bradykinin (Bk, 1 pM —
10 nM), adenosine diphosphate (ADP, 10 nM —
1 mM), adrenaline (1—10 mM) or acetylcholine
Figure 11. Pulmonary sequestration of platelets in the isolated blood-
perfused rat lung, challenged with either LPS or L-
NAME+LPS (see legend to Fig. 10). LPS induced an imme-
diate retention of platelets in pulmonary circulation that last-
ed approximately 1 h. L-NAME+LPS produced a similar
pulmonary sequestration of platelets, although it was irre-
versible and associated with lung injury. Data show
mean–SEM for n=6 experiments.
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(10—100 mM) may cause 4- to 8-fold increase in
[Ca2+]i. Bradykinin is known to release EDRF(NO)
from BAEC in a [Ca2+]i-dependent manner,
although calcium channel antagonists do not inhib-
it this release [39] Much less active stimulators of
[Ca2+]i in BAEC are Ôtissue typeÕ inhibitors of angio-
tensin converting enzyme (ACE-I), such as quinapril
or perindopril (10—30 mM), which, in our opinion,
seem to act as Ôbradykinin potentiating factorsÕ
(BPF) (40), i.e. kininase II inhibitors, rather than as
angiotensin I/II convertase inhibitors [41]. We
believe that the bradykinin-mediated activation of
endothelial protective secretory function by Ôtissue
ACE-IÕ is responsible for a substatial reduction in
the death rate from myocardial infarction and
ischaemic stroke in high risk patients treated with
ramipril (another Ôtissue ACE-IÕ) [42].
Indeed, as early as fifteen years ago we reported
that bradykinin at a concentration of 20 nM or
Figure 13. Electron micrograph of pulmonary capillary of isolated
blood-perfused rat lung shortly after a challenge with L-
NAME+LPS. Capillary endothelial cells (EC) and epithelial
cell type I (EpI) are damaged as evidenced by decrease in
electron density and oedema of these cells. Inside capillary
vessel sequestrated platelets (P) and neutrophil (N) are
seen. In alveolar space protein rich fluid (PF) and erythro-
cytes (Er) are present. Magnification 6000x.
Figure 12. Light micrograph of isolated blood-perfused rat lung shortly after a challenge with LPS (upper panel) and L-NAME+LPS (lower panel).
Immediate phase of lung response to LPS was not associated with changes in lung histology (upper panel) while injection of L-
NAME+LPS induced massive alveolar haemorrhages (lower panel). Hematoxylin-eosin stain, Objective magnification 40x.
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A23187 at a concentration of 2 mM would both
result in a coupled release of EDRF(NO) and PGI2
from cultured porcine aortic endothelial cells [43].
The order of potencies of bradykinin and A23187
to release PGI2 and EDRF(NO) in a coupled man-
ner from BAEC [44] was similar to that for increas-
ing [Ca2+]i, as reported here. No doubt, bradykinin
is the most potent physiological stimulator for
increasing [Ca2+]i in BAEC. ADP is next to it. In
vivo, the coupled release of PGI2 and EDRF(NO)
by ADP is likely to occur when endogenous ADP is
being released from aggregating platelets, and then
ADP-triggered endothelial defence against throm-
bosis turns up. In vivo, the coupled release of PGI2
and EDRF(NO) by bradykinin may be expected
when this peptide is locally generated by vascular
endothelium, provided that bradykinin would suc-
Figure 14. Electron micrograph of pulmonary microvessel of isolated
blood-perfused rat lung challenged with L-NAME+LPS.
Neutrophils (N), erythrocytes (Er) and aggregated platelets
(P) are seen inside the lumen of pulmonary microvessel.
Inside a neutrophil is visible internalised LPS with electron
dense lipid A, and less osmophilic polisaccharide chains of
the LPS structure. Magnification 10000x.
Figure 15. A scheme of inhibitory action of Ôtissue typeÕ ACE-I (e. g. quinapril or perindopril) on endothelial ACE. Inhibition of this enzyme allows
endothelial kinins to escape the distruction and to activate kinin B2 receptor. In consequence, via protein G [Ca+2]i is mobilized and
calmodulin complex is formed. This last activates a number of enzymes such as phospholipase A2 (PLA2), cyclooxygenase-1 (COX-1),
and NO synthase (NOS-3), which are responsible for synthesis and release of endothelial defensive mediators (eg. PGI2, NO, EDHF).
12
Basic Research
capillary lumen
activation of complement 
air space 
endothelium  
epithelium 
bacterial LPS
activation of platelets
unihibited by 
endogenous NO
excessive constriction of 
pulmonary vessels and airways
activation of neutrophils 
unihibited by 
endogenous NO 
cysLTs
selectin P
PSGL-1
PSGL-1
selectin P
TXA2
PAF
vascular-alveolar barrier injury
complement
Microvascular lung injury induced by LPS in NO-deficient lung
capillary lumen
activation of complement 
air space
endothelium 
epithelium
bacterial LPS
activation of platelets 
controlled by 
endogenous NO
Transient constriction of 
pulmonary vessels and airways
NO NONO
NO
NO
activation of neutrophils 
controlled by endogenous NO
TXA2
PAF
v ascular-alv eolar barr ier
complement 
Role of nitric oxide (NO) in chain of events 
triggered by LPS in pulmonary microcirculation 
Figure 16. Role of pulmonary NO in the early response of the lung to LPS (a) and consequences of pharmacological removal of pulmonary NO,
which are showing up as microvascular lung injury by endogenous toxins (b).
a)
b)
13
Gryglewski RJ et al — Significance of endothelial prostacyclin and nitric oxideÉ
ceed escaping destruction by the kininase II func-
tion of endothelial caveolar ACE (Fig. 15). Indeed,
we show presently that in vivo in rats quinapril and
perindopril activate the secretory endothelial func-
tion through a bradykinin mechanism. In vivo
thrombolytic response has been used, and allowed
to demonstrate, that quinapril or perindopril
induced, bradykinin-mediated thrombolysis is
mediated predominantly by PGI2. EDRF(NO) plays
only a permissive role, while t-PA may participate
in a late phase of thrombolysis.
Bradykinin is a potent agonist of the receptor B2
mediated instantaneous endothelial secretory
response. However, in this paper we report that
bradykinin may have yet another endothelial me-
chanism of action. In cultured HUVEC incubated
with bradykinin at a low concentration of 10 nM
for four hours we observed an induction of tran-
scripts for three enzymes: haemooxygenase 1
(HO-1), prostaglandin E synthase (PGE-S), cyclo-
oxygenase 2 (COX-2) and NO synthase 2 (NOS-2).
The potency of induction for corresponding
mRNAs decreased in order HO-1>PGE-S>COX-
2>>NOS-2. Actually, the expression of NOS-2 m-
RNA was only slightly touched by bradykinin. We
have not been as yet studying effects of bradykinin
on corresponding enzymic proteins or on their
activities. Would they go along with their mRNAs,
then bradykinin acts as a ÔmicrocytokineÕ enzyma-
tic inducer. Induction of HO-1 is associated not
only with an increased production of CO but also
with an increased consumption of haeme required
as a prosthetic moiety both in cyclooxygenase and
in NO synthase, as well as in a number of other
haemoprotein enzymes [45]. The above pattern of
induction of endothelial mRNAs may suggest that
the delayed microcytokine-like effect of bradykinin
on activities of COX-2 and NOS-2 will be tem-
pered by a concomitant rise in HO-1 activity, and
therefore the net ÔinductiveÕ effect of bradykinin on
prostanoid generation might be stronger than its
effect on NO generation. This assumption requires
an experimental confirmation, especially that an
increased generation of CO by inducible HO-1
may assist vasodepressor function of PGI2 or NO
[46]. Not long ago, the involvement of cytosolic
phosholipase A2 in bradykinin-mediated release of
PGI2 from HUVEC was reported [47]. As it has
been said PGI2 is a major endothelial mediator
involved in housekeeping function of the conduc-
tance blood vessels of peripheral circulation, while
in microcirculation PGE2 seems to play a similar
role. This is why induction by bradykinin of PGE-S
in endothelial cells of microcirculation would be of
great significance for controlling inflammatory res-
ponses, especially those mediated by activated
neutrophils whose adenylate cyclase is sensitive to
stimulation by PGE2 rather than by PGI2.
In pulmonary circulation NO but not PGI2 protects
endotoxaemic lung from damage both in vivo [48]
and in isolated blood perfused rat lung, as shown
presently. In this preparation an immediate bron-
choconstrictor and vasoconstrictor responses to
bacterial lipopolysaccharide (LPS) are mediated by
platelet activating factor (PAF) and thromboxane
A2 (TXA2) being released from activated neu-
trophils and platelets, respectively. Usually these
responses are transient, since LPS-induced, com-
plement-dependent activation of blood morpho-
logical elements are tempered by endogenous NO.
The above reasoning is supported by our finding
that pharmacological blockade of NOS enforced
LPS to precipitate unrestricted adhesion of platelets
and neutrophils to each other and to endothelial
cells. These interactions mediated by the comple-
ment system and selectin P draw a scenario fa-
vourable for transcellular synthesis of cysteinyl
leukotrienes (cyst-LTs)  [5,6]. In absence of endo-
genous NO the immediate response to LPS is no
more transient. Now TXA2, PAF and cyst-LTs have
their chance to act in an unrestricted way leading
to the arrest of all lung functions, vascular and bro-
nchial constriction, acute microvascular lung injury
and haemorrhagic lung oedema. It is tempting to
speculate that the role of pulmonary NO is to
ensure the quick and safe elimination from blood
of bacterial LPS internalised in neutrophils. Indeed,
platelets-stimulated [49] and otherwise stimulated
neutrophils are main phagocytising cells in blood
[50].
It goes as no surprise that the safeguard role of NO
in pulmonary endothelium in the early endotox-
aemia cannot be replaced by PGI2. It is NO but
not PGI2 that inhibits intercellular adhesion [51,
52]. Although PGI2 is a potent inhibitor of platelet
aggregation [53] it hardly influences platelet adhe-
sion [54] and it has virtually no effect on leukocyte
function [4]. Thus, pulmonary NO appears to be
the major if not the only endogenous mediator that
alleviates the necessary but dangerous events lead-
ing to removal of bacterial LPS from pulmonary cir-
culation (Fig. 16).
Summing up, endothelial bradykinin seems to re-
gulate through a calcium-dependent mechanism
the activities of dioxygenases, which produce
14
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prostacyclin and nitric oxide in the vascular
endothelium. This immediate action of bradykinin
is supplemented by its delayed induction of tran-
scripts for several endothelial enzymes. Irrespe-
ctively to mechanisms of their generation prostacy-
clin and prostaglandin E2 are likely to play a major
protective role in peripheral circulation, whereas
nitric oxide is a major defender in pulmonary cir-
culation.
CONCLUSION
1. In peripheral circulation vasoprotective function
of the endothelium is mediated predominantly
by prostacyclin (PGI2) whereas in pulmonary circu-
lation it is mediated mainly by nitric oxide (NO).
2. In cultured endothelial cells, of all receptor ago-
nists studied, bradykinin (Bk) proved to be the
most potent stimulator to increase their free
cytoplasmic calcium [Ca2+]i.
3. Bradykinin (Bk) activates endothelial enzymes by
fast rising of free cytoplasmic calcium [Ca2+]i or
it induces transcripts of endothelial enzymes in a
delayed ÔmicrocytokineÕ — like manner.
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